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Background: Gametocytes are responsible for transmission of malaria from human to mosquito. Artemisinin
combination therapy (ACT) reduces post-treatment gametocyte carriage, dependent upon host, parasite and
pharmacodynamic factors. The gametocytocidal properties of antimalarial drugs are important for malaria
elimination efforts. An individual patient clinical data meta-analysis was undertaken to identify the determinants of
gametocyte carriage and the comparative effects of four ACTs: artemether-lumefantrine (AL), artesunate/amodiaquine
(AS-AQ), artesunate/mefloquine (AS-MQ), and dihydroartemisinin-piperaquine (DP).
Methods: Factors associated with gametocytaemia prior to, and following, ACT treatment were identified in
multivariable logistic or Cox regression analysis with random effects. All relevant studies were identified through a
systematic review of PubMed. Risk of bias was evaluated based on study design, methodology, and missing data.
Results: The systematic review identified 169 published and 9 unpublished studies, 126 of which were shared with the
WorldWide Antimalarial Resistance Network (WWARN) and 121 trials including 48,840 patients were included in the
analysis. Prevalence of gametocytaemia by microscopy at enrolment was 12.1 % (5887/48,589), and increased with
decreasing age, decreasing asexual parasite density and decreasing haemoglobin concentration, and was higher in
patients without fever at presentation. After ACT treatment, gametocytaemia appeared in 1.9 % (95 % CI, 1.7–2.1) of
patients. The appearance of gametocytaemia was lowest after AS-MQ and AL and significantly higher after DP
(adjusted hazard ratio (AHR), 2.03; 95 % CI, 1.24–3.12; P = 0.005 compared to AL) and AS-AQ fixed dose combination
(FDC) (AHR, 4.01; 95 % CI, 2.40–6.72; P < 0.001 compared to AL). Among individuals who had gametocytaemia before
treatment, gametocytaemia clearance was significantly faster with AS-MQ (AHR, 1.26; 95 % CI, 1.00–1.60; P = 0.054) and
slower with DP (AHR, 0.74; 95 % CI, 0.63–0.88; P = 0.001) compared to AL. Both recrudescent (adjusted odds ratio (AOR),
9.05; 95 % CI, 3.74–21.90; P < 0.001) and new (AOR, 3.03; 95 % CI, 1.66–5.54; P < 0.001) infections with asexual-stage
parasites were strongly associated with development of gametocytaemia after day 7.
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Conclusions: AS-MQ and AL are more effective than DP and AS-AQ FDC in preventing gametocytaemia shortly after
treatment, suggesting that the non-artemisinin partner drug or the timing of artemisinin dosing are important
determinants of post-treatment gametocyte dynamics.
Keywords: Malaria, Plasmodium falciparum, Drug resistance, GametocyteBackground
Malaria remains a leading cause of morbidity and mortal-
ity in endemic countries, with an estimated 584,000 deaths
and 198 million clinical cases of malaria globally in 2013
[1]. Considerable progress has been made in the last
decade in reducing the burden of malaria by wide-scale
deployment of insecticide-treated nets and efficacious ar-
temisinin combination therapy (ACT) as first-line anti-
malarial treatment [2]. To maintain these gains and
further move towards malaria elimination, a specific focus
on malaria reducing interventions is needed [3]. The
transmission of malaria to mosquitoes depends on mature
sexual stage parasites, gametocytes, in the human periph-
eral blood. Plasmodium falciparum gametocytaemia has
been associated with asexual parasite densities, the dur-
ation of malaria symptoms, anaemia and immunity [4, 5].
A large fraction of gametocyte-positive individuals are
asymptomatic and the contribution of this asymptomatic
reservoir to onward malaria transmission is considerable
in many endemic settings [6]. As a consequence, efforts to
reduce malaria transmission by antimalarial treatment
depend for a large extent on the proportion of malaria-
infected individuals that receive treatment [7]. Upon
initiation of treatment, gametocytes may persist for several
weeks after the clearance of asexual parasites with their
longevity and infectivity depending on the treatment dis-
pensed [8, 9], dosing [10] and host immunity [5].
ACT is now recommended universally for the treat-
ment of uncomplicated falciparum malaria. Artemisinins
are highly effective against the pathogenic asexual para-
site stages [11] and immature gametocytes [12, 13],
resulting in a substantial reduction of post-treatment
malaria transmission compared to non-artemisinin drugs
[9, 14, 15]. The wide-scale deployment of ACTs has been
associated with substantial reductions in disease burden
across a range of endemic settings [16, 17]. Nevertheless,
the transmission reducing effects of ACT may be incom-
plete because of limited efficacy of artemisinins against
mature gametocytes, permitting residual transmission in
the first weeks after treatment [9, 15]. Moreover, differ-
ences in artemisinin dosing, timing and partner drugs
affect their gametocytocidal properties [18, 19].
Because gametocytes are only detected in a fraction
of patients by microscopy, individual trials are often
insufficiently powered to compare gametocytocidal
properties between ACTs or disentangle host andparasite factors that influence gametocyte dynamics.
To address this, a pooled analysis of individual-level
patient data was undertaken in patients before and
after treatment with artemether-lumefantrine (AL),
artesunate-amodiaquine (AS-AQ), artesunate-mefloquine
(AS-MQ), and dihydroartemisinin-piperaquine (DP).
Methods
Data pooling
A search was conducted in PubMed in September 2014 to
identify all antimalarial clinical trials published between
1990 and 2014, in which gametocytes were recorded using
the search strategy described in the legend of Additional
file 1: Table S1. Those who had contributed studies previ-
ously to the WorldWide Antimalarial Resistance Network
(WWARN) data repository were also invited to participate
and asked whether they were aware of any unpublished or
ongoing clinical trials involving ACTs, and these add-
itional unpublished studies were also requested. Investiga-
tors were invited to participate in this pooled analysis if
their studies included (1) uncomplicated P. falciparum
malaria (alone or mixed infection with another species);
(2) asexual parasite quantification at enrolment; (3) gam-
etocyte quantification or prevalence at enrolment; (4) well
described methodology for quantifying asexual parasites
and gametocytes; and (5) haemoglobin (or haematocrit)
estimation at enrolment.
Individual study protocols were available for all trials
included, either from the publication or as a metafile
submitted with the raw data. Individual patient data
from eligible studies were shared, collated and standar-
dised using a previously described methodology [10, 20].
Study reports generated from the formatted datasets were
sent back to investigators for validation or clarification.
All parasite data were based on microscopic observations.
Statistical analysis
Statistical analyses were carried out using STATA
(Version 13.1) according to an a priori Statistical
Analysis Plan [20]. Briefly, we determined: (1) preva-
lence of gametocytaemia at enrolment (regardless of
subsequent treatment regimen); (2) risk of gametocy-
taemia in patients presenting with no gametocytaemia
on enrolment; and (3) time to clearance of gametocy-
taemia in patients presenting with gametocytaemia.
For the comparison of ACT regimens, the analysis was
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parasitaemia recorded during follow-up. Multivariable
models with random effects were fitted to adjust for
study and site heterogeneity: logistic for outcome (1)
and Cox regression (with shared frailty) for outcomes
(2) and (3). The effect of the following baseline covari-
ates was examined: age, sex, log asexual parasite dens-
ity, hyperparasitaemia (asexual parasitaemia > 200,000
parasites per μL), haemoglobin/haematocrit, anaemia
(haemoglobin concentration < 10 g/dL), presence of/history
of fever, nutritional status (based on weight-for-age z-scores
in children < 5 years of age), treatment dose of artemisinin
derivative, geographic region and malaria transmission in-
tensity [21]. Indicators of parasite clearance time included
asexual parasite prevalence and log asexual parasite dens-
ity on days 1, 2, 3 and the area under the curve of asexual
parasite density during days 0–3. Fractional polynomials
[22] were used to define the nonlinear relationship be-
tween age, haemoglobin concentration and asexual
parasite density and the risk of gametocytaemia; to
maintain stability, these models were fitted to data
from patients ≤ 70 years of age, with haemoglobin be-
tween 5 and 18 g/dL and with 500–200,000 asexual
parasites per μL. Target dosing for the artemisinin
components of the ACTs was defined according to
WHO guidelines: ≥ 8.4 mg/kg for AL and ≥ 6 mg/kg for
AS-AQ, AS-MQ and DP [23].
Gametocyte carriage at any time after treatment in
patients with no recurrent parasitaemia, patients with
recrudescent infections and patients with reinfections
were compared using multilevel logistic regression models
with random effects for study site and subject.
Methods to detect gametocytes by microscopy differed
between trials. The sensitivity of microscopy methods
was included in the analyses, by classifying studies into
one of four categories, as follows: (1) studies in which
slides were specifically read for gametocytes, reviewing at
least 100 microscopic high power fields or against ≥ 1000
white blood cells (WBC) (4 studies); (2) microscopists spe-
cifically instructed to record gametocytes but slides were
primarily read for asexual parasites; ≥ 100 microscopic
high power fields per ≥ 1000 WBC were read (26 studies);
(3) microscopists were specifically instructed to record ga-
metocytes; 50–99 microscopic high power fields per 500–
999 WBC were read (33 studies); (4) microscopists were
not specifically instructed to record gametocytes or the
number of examined high power fields was < 50 or the
number of WBC was < 500 (40 studies). For 18 studies,
the information on the sensitivity of the microscopy was
not available.
Risk of bias within studies was assessed based on
(1) study design (randomization, sequence generation,
blinding); (2) methodology for gametocyte detection;
and (3) the number and proportion of patients with(a) missing outcomes and (b) missing baseline covariates
(age, weight, parasitaemia, temperature, haemoglobin/
haematocrit). For the final models, two sets of sensitivity
analyses were performed. Firstly, a model was refitted with
each study’s data excluded, one at a time, and a coefficient
of variation around the parameter estimates calculated.
This would identify any influential studies, that is, studies
with unusual results (due to variations in methodology,
patient population, or other reasons) that affect the overall
pooled analysis findings. Secondly, for the outcome meas-
ure time to gametocytaemia, the impact of incomplete
gametocyte carriage data was investigated by refitting the
final multivariable model in a subset of patients with
complete weekly data for 28 days.
Ethical approval
All data included in this analysis were obtained in ac-
cordance with the laws and ethical approvals applicable
to the countries in which the studies were conducted,
and were obtained with the knowledge and consent of
the individual to which they relate. Data were fully anon-
ymised either before or during the process of uploading
to the WWARN repository. Ethical approval to conduct
individual participant data pooled analyses was granted
to WWARN by the Oxford Tropical Research Ethics
Committee (OXTREC-48-09).
Results
Characteristics of included studies
In total, 169 published clinical trials were identified that
recorded P. falciparum gametocytes at enrolment or
during follow-up. Investigators of 117 clinical trials
(59,458 patients) agreed to contribute their data. In
addition, nine unpublished studies (1,803 patients) were
shared, one of which was published subsequently. After
exclusion of duplicate studies, studies in returning trav-
ellers, multiple infection episodes and participants with
protocol violations, 48,840 study participants from 121
individual clinical trials were retained (Fig. 1; full list of
studies in Additional file 1: Table S1).
Baseline characteristics
The majority of participants were from Africa (34,377;
70.4 %) or Asia (13,546; 27.7 %) with a minority coming
from South America (917; 1.9 %) (Table 1). Most studies
involved treatment with an ACT (68.3 % of all partici-
pants (33,356/48,840)) with AL being the most com-
monly used regimen (27.1 %; 13,217/48,840) (Table 2).
AS-AQ was given to 17.4 % (8488/48,840) of partici-
pants; 50.4 % (4278/8488) of these received a fixed dose
combination (FDC), others received a non-fixed dose
combination (42.9 %; 3637/8488) or co-blistered AS and
AQ (6.8 %; 573/8488). The analyses for AS-AQ were re-
stricted to the FDC regimen (AS-AQ FDC). AS-MQ was
Fig. 1 Study profile
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most of the patients (88.1 %; 4580/5198) as a loose com-
bination. The following proportions of patients received
less than the recommended dose, AL: 8.3 % (1088/
13,086); AS-AQ FDC: 0.1 % (2/4262); AS-MQ: 0.8 %
(38/4769) DP: 23.6 % (1488/6315).
Determinants of gametocytaemia at enrolment
Prevalence of gametocytaemia at enrolment was 12.1 %
(5887/48,589), and was not significantly influenced by the
slide reading method. In Africa, fractional polynomial ana-
lysis indicated a gradual decline in the proportion of
gametocyte-positive smears with increasing age (Fig. 2); in
Asia there was an initial increase in prevalence of gameto-
cytaemia with increasing age in the first 20 years of life,
followed by a decline with increasing age thereafter. The
differences between African and Asian sites in the associ-
ation between age and prevalence of gametocytaemia
remained apparent when the analysis was restricted to
studies with the highest sensitivity of gametocyte detec-
tion (≥100 high power fields or ≥ 1,000 WBC examined
specifically for gametocytes) and when restricted to chil-
dren below 5 years of age (Additional file 2: Figure S1).
Prevalence of gametocytaemia at enrolment was nega-
tively associated with haemoglobin concentration in all
three continents (Table 3; Fig. 2).In Asia, there was a gradual decline in prevalence of
gametocytaemia with increasing asexual parasite density
across the entire range of asexual parasite densities that
were observed (Fig. 2). In Africa, when asexual parasite
density exceeded 10,000 parasites/μL, there was a grad-
ual decline in prevalence of gametocytaemia with in-
creasing asexual parasite density. At lower parasite
densities the uncertainty around estimates was larger
and the association between prevalence of gametocytae-
mia and the logarithm of asexual parasite density was
non-linear (Fig. 2). These differences between African
and Asian sites remained apparent when the analysis
was restricted to studies with the highest sensitivity of
gametocyte detection (Additional file 2: Figure S1).
In all regions, individuals presenting with fever
(axillary temperature >37.5 °C or reporting of febrile
symptoms) were less likely to present with gametocytae-
mia and this remained significant after adjusting for co-
variates in both African (adjusted odds ratio (AOR),
0.63; 95 % CI, 0.58–0.69; P < 0.001) and Asian (AOR,
0.81; 95 % CI, 0.69–0.95; P = 0.011) patients. Male
gender was a predictor of prevalence of gametocytaemia
at enrolment in studies in Asia (AOR, 1.25; 95 % CI,
1.07–1.46; P = 0.004) and South America (AOR, 2.14;
95 % CI, 1.33–3.45; P = 0.002) but not Africa (Table 3).
Children under 5 years of age who were malnourished
Table 1 Demographic and baseline characteristics
Africa Asia South America
n evaluated n (%) or median (Range) n evaluated n (%) or median (Range) n evaluated n (%) or median (Range)
Age
< 1 year 34361 2502 (7) 13545 60 (0) 915 0 (0)
1–4 years 34361 20473 (60) 13545 1377 (10) 915 0 (0)
5–11 years 34361 6775 (20) 13545 3601 (27) 915 111 (12)
≥ 12 years 34361 4611 (13) 13545 8507 (63) 915 804 (88)
Age (years) 34361 3.3 (0–86.7) 13545 15.0 (0–88.0) 915 23.0 (5.0 – 65.0)
Haemoglobin (g/dL) 24771 9.9 (5.0–19.7) 3139 11.1 (5.0–20) 603 12.2 (7.0–17.3)
Haematocrit (%) 5938 32.8 (15.0–49.8) 8076 36.0 (15.0–50.0) 604 37.0 (18.0 – 50.0)
Derived haemoglobin (g/dL) 26806 9.9 (3.6–19.7) 10937 11.6 (3.6–20) 606 12.2 (7.0–17.3)
Anaemia 26806 13313 (50) 10937 3882 (26) 606 48 (8)
Temperature (°C) 33776 37.9 (34.0–41.5) 10828 37.7 (34.0–42.0) 914 37.5 (35.1 – 42.0)
Fever 34199 21213 (62) 10981 6862 (53) 914 438 (48)
History of fever 7244 6826 (94) 2515 2291 (91) 0 . (.)
Parasitaemia (/μL) 34376 20560 (2–250000) 13546 9720 (0–249818) 915 4514 (0–149925)
Hyperparasitaemia 34376 3223 (9) 13546 1908 (14) 915 3 (0)
Mixed infection 34377 0 (0) 13546 903 (7) 917 0 (0)
Sex (male) 33411 17223 (52) 13243 8015 (61) 917 566 (62)
Weight-for-age z-score
< 5 years 21765 –0.89 (–5.93 to 4.69) 1403 –1.58 (–5.88 to 4.71) 0 –
< 1 year 2323 –0.68 (–5.93 to 4.69) 56 –0.67 (–4.45 to 4.71) 0 –
1–2 years 9708 –0.96 (–5.91 to 4.54) 414 –1.61 (–5.53 to 4.37) 0 –
3–4 years 8305 –0.99 (–5.3 to 4.38) 869 –1.69 (–5.88 to 2.62) 0 –
Underweight
< 5 years 21765 3918 (18) 1403 517 (37) 0 –
< 1 year 2323 373 (16) 56 8 (14) 0 –
1–2 years 9708 1846 (19) 414 150 (36) 0 –
3–4 years 8305 1503 (18) 869 338 (39) 0 –
Transmission intensity
Low 34105 10063 (30) 13246 11884 (90) 917 917 (100)
Moderate 34105 10659 (31) 13246 1362 (10) 917 0 (0)
High 34105 13383 (39) 13246 0 (0) 917 0 (0)
Derived haemoglobin, conversion from haematocrit: haemoglobin = (haematocrit–5.62)/2.60 [40]; Anaemia, haemoglobin < 10 g/dL; Fever, temperature > 37.5 °C;
Hyperparasitaemia, parasitaemia > 100,000 parasites per μL; Weight-for-age z-score, calculated using “igrowup” package developed by WHO [41] in children < 5 years of
age; Underweight, weight-for-age z-scores < –2
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of gametocytaemia at enrolment compared to well-
nourished children in Africa (OR, 1.23; 95 % CI,
1.11–1.37; P < 0.001) and in Asia (OR, 1.40; 95 % CI,
1.03–1.92; P = 0.032) but this was not significant in
the multivariable analysis (Additional file 3: Table S2).
Gametocytaemia after artemisinin combination therapy
No gametocytaemia at enrolment
Amongst the 18,388 individuals presenting without pa-
tent gametocytaemia by microscopy who were treatedwith an ACT, the Kaplan–Meier estimate of risk of ap-
pearance of gametocytaemia within 28 days was 1.9 %
(95 % CI, 1.7–2.1) (Fig. 3a). This proportion was similar
in African and Asian studies. After controlling for
confounding factors, the risk of appearance of gameto-
cytaemia correlated negatively with age, haemoglobin
concentration, fever and asexual parasite density at
enrolment (Table 4). Appearance of gametocytaemia
was lowest after AS-MQ or AL treatment and signifi-
cantly higher after DP (adjusted hazard ratio (AHR),
2.03; 95 % CI, 1.24–3.32; P = 0.005 compared to AL)
Table 2 Overview of treatment, artemisinin combination treatment dosing and formulation
Treatment Dosing
n evaluated N (%) n evaluated Partner drug dose
median (Range)
Artemisinin derivative dose
median (Range)
Underdosed n (%)
AL 48840 13217 (27 %) 13086 68.6 (8.9–144.0) 11.4 (1.5–24.0) 1008 (8.3 %)
AS-AQ 48840 8488 (17 %) 8395 31.9 (10.0–91.8) 12.4 (4.0–52.6)
AS-AQ formulation:
Co-blistered nFDC 8488 573 (7 %) 573 37.4 (14.8–91.8) 13.5 (4.8–30.0)
FDC 8488 4278 (50 %) 4262 32.4 (14.5–81.0) 12.0 (5.4–30.0) 2 (0.1 %)
nFDC 8488 3637 (43 %) 3560 30.1 (10.0–60.0) 12.5 (4.0–52.6)
AS-MQ 48840 5198 (11 %) 4535 25.0 (4.2–85.0) 12.0 (2.3–62.1) 38 (0.8 %)
DP 48840 6453 (13 %) 6315 53.3 (14.5–182.9) 6.7 (1.8–22.9) 1488 (23.6 %)
Other, including non-ACT 48840 15484 (32 %)
AL, Artemether-Lumefantrine; AS-AQ, Artesunate-Amodiaquine; AS-MQ, Artesunate-Mefloquine; DP, Dihydroartemisinin-piperaquine; nFDC, Non-fixed dose combination,
FDC, Fixed dose combination; Underdosed defined as ≤ 8.4 mg/kg artemether dose in AL, < 6 mg/kg dose of artesunate or DHA in other regimens [19]
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compared to AL) (Fig. 3a, Table 4). A dose of the arte-
misinin component < 8 mg/kg was associated with an
increased chance of appearance of gametocytaemia
after treatment with DP (AHR, 2.78; 95 % CI, 1.18–Fig. 2 Relationship between gametocytaemia on enrolment and patient ag
The predicted probability of gametocyte carriage at enrolment is plotted fr
area the 95 % confidence interval6.55; P = 0.020) but not after treatment with any of the
other ACTs (Additional file 4: Table S3). No associ-
ation was observed for a dose of the artemisinin com-
ponent < 6 mg/kg either for all treatment combined or
for DP alone.e, baseline haemoglobin concentration and asexual parasite density.
om the multivariate model; the line indicates the best fit, the shaded
Table 3 Risk factors for gametocyte prevalence at enrolment
Africa Asia South America
Parameter Nobs/Npos (%) OR (95 % CI) P value Nobs/Npos (%) OR (95 % CI) P value Nobs/Npos (%) OR (95 % CI) P value
Univariable model
Age
< 1 year 2492/403 (16.2) 2.506 (1.978–3.174) <0.001 60/12 (20.0) 2.240 (1.124–4.460) 0.022 0/0
1–4 years 20419/2799 (13.7) 2.558 (2.082–3.144) <0.001 1374/297 (21.6) 2.095 (1.777–2.469) <0.001 0/0
5–11 years 6715/495 (7.4) 1.523 (1.245–1.864) <0.001 3587/563 (15.7) 1.535 (1.354–1.740) <0.001 111/19 (17.1) 0.834 (0.485–1.432) 0.510
12+ years 4571/179 (3.9) – 8438/977 (11.6) – 803/139 (17.3) –
Age (years) 34197/3876 (11.3) 0.961 (0.952–0.971) <0.001 13459/1849 (13.7) 0.975 (0.971–0.980) <0.001 914/158 (17.3) 0.995 (0.983–1.008) 0.453
Derived haemoglobin (g/dL) 26693/3394 (12.7) 0.785 (0.767–0.803) <0.001 10854/1433 (13.2) 0.664 (0.645–0.683) <0.001 606/120 (19.8) 0.600 (0.523–0.688) <0.001
Anaemia
Yes 13441/2322 (17.3) 2.062 (1.888–2.253) <0.001 2871/795 (27.7) 4.846 (4.258–5.516) <0.001 48/22 (45.8) 3.972 (2.162–7.297) <0.001
No 13252/1072 (8.1) Reference 7983/638 (8.0) Reference 558/98 (17.6) Reference
Fever
Yes 21115/1910 (9.1) 0.583 (0.538–0.631) <0.001 5816/566 (9.7) 0.738 (0.649–0.839) <0.001 438/54 (12.3) 0.529 (0.367–0.762) 0.001
No 12925/1950 (15.1) Reference 5107/730 (14.3) Reference 476/105 (22.1) Reference
Sex
Female 16119/1782 (11.1) 0.976 (0.908–1.048) 0.501 5205/754 (14.5) 1.083 (0.973–1.206) 0.145 350/52 (14.9) 0.756 (0.525–1.089) 0.133
Male 17128/1963 (11.5) Reference 7952/1085 (13.6) Reference 566/107 (18.9) Reference
Log10 Parasitaemia (/μL) 34212/3879 (11.3) 0.590 (0.554–0.629) <0.001 13442/1833 (13.6) 0.726 (0.677–0.779) <0.001 914/158 (17.3) 0.333 (0.212–0.524) <0.001
Hyperparasitaemia
Yes 3217/160 (5.0) 0.389 (0.328–0.460) <0.001 1892/289 (15.3) 0.441 (0.338–0.575) <0.001 0/0
No 30995/3719 (12.0) Reference 12568/1743 (13.9) Reference 912/158 (17.3)
Mixed infection
Yes 892/106 (11.9) 1.112 (0.880–1.404) 0.374
No 13496/1817 (13.5) Reference
Weight-for-age z-score 21701/2996 (13.8) 0.932 (0.901–0.966) <0.001 1403/305 (21.7) 0.815 (0.723–0.919) 0.001 0/0
Underweight
Yes 3904/651 (16.7) 1.234 (1.113–1.368) <0.001 517/144 (27.9) 1.404 (1.029–1.915) 0.032 0/0
No 17797/2345 (13.2) Reference 886/161 (18.2) Reference 0/0
TIA
Low 9995/802 (8.0) 0.990 (0.674–1.454) 0.959 11799/1383 (11.7) 0.251 (0.074–0.850) 0.026 871/147 (16.9)
Moderate 10575/1069 (10.1) 1.074 (0.801–1.440) 0.631 1361/438 (32.2) Reference 0/0
High 13371/2000 (15.0) Reference 0/0 0/0
W
W
A
RN
G
am
etocyte
Study
G
roup
BM
C
M
edicine
 (2016) 14:79 
Page
7
of
18
Table 3 Risk factors for gametocyte prevalence at enrolment (Continued)
Multivariable model 26669 / 3389 (12.7) 8919 / 929 (10.4) 605 /120 (19.8)
Age (years) 0.984 (0.974–0.994) 0.001 0.988 (0.982–0.994) <0.001
Derived haemoglobin (g/dL) 0.788 (0.770–0.807) <0.001 0.672 (0.648–0.697) <0.001 0.581 (0.502–0.672) <0.001
Log10 Parasitaemia (/μL) 0.617 (0.575–0.662) <0.001 0.735 (0.669–0.807) <0.001 0.330 (0.184–0.592) <0.001
Fever 0.633 (0.579–0.691) <0.001 0.811 (0.689–0.954) 0.011
Sex (M) 1.252 (1.073–1.462) 0.004 2.144 (1.331–3.454) 0.002
Logistic univariable and multivariable mixed effects analysis by region with presence of gametocytaemia at enrolment as dependent variable. Nobs, number of observations; Npos, number of positive observations;
Weight-for-age z-score, calculated using “igrowup” package developed by WHO [41] in children < 5 years of age; Underweight, weight-for-age z-scores < –2; TIA, Transmission intensity areas; Derived haemoglobin,
conversion from haematocrit: haemoglobin = (haematocrit–5.62)/2.60 [40]; Anaemia, haemoglobin < 10 g/dL; Fever, temperature > 37.5 °C; Hyperparasitaemia, parasitaemia > 100,000 parasites per μL
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Fig. 3 Gametocyte carriage by artemisinin-combination therapy. a Development of gametocytaemia after treatment with artemether-lumefantrine
(AL), artesunate-amodiaquine fixed-dose combination (AS-AQ-FDC), artesunate-mefloquine (AS-MQ) or dihydroartemisinin-piperaquine (DP); evaluated
in patients with no gametocytes on enrolment. b Gametocyte clearance, adjusted for initial gametocyte count, evaluated in patients with gametocytes
on enrolment. Only patients with no recurrent infection recorded were included
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A total of 2433 patients treated with an ACT were
gametocytaemic at enrolment and had no recurrent in-
fection. Overall, 57.4 % (95 % CI, 55.4–59.4) of thesepatients cleared gametocytaemia by day 7, 78.4 % (95 %
CI, 76.5–80.2) by day 14 and 88.2 % (95 % CI, 86.6–
89.6) by day 21. The only independent determinants of
gametocyte clearance were initial gametocyte density
Table 4 Factors associated with the development of gametocytaemia after enrolment in individuals without microscopically
detected gametocytes before treatment with artemisinin combination therapy
Parameter Nobs Npos per Hazard ratio (95 % CI) P value
Univariable model
ACTa
AS-MQ 3082 20 0.6 0.763 (0.392–1.484) 0.425
DP 3855 93 2.4 2.746 (1.773–4.253) <0.001
AS-AQ: FDC 2919 151 5.2 4.094 (2.540–6.600) <0.001
AL 8532 97 1.1 Reference
Agea
< 1 year 776 23 3.0 2.435 (1.268–4.676) 0.008
1–4 years 7772 236 3.0 2.780 (1.698–4.552) <0.001
5–11 years 4102 58 1.4 1.928 (1.225–3.035) 0.005
12+ years 5735 44 0.8 Reference
Age (years) 18385 361 2.0 0.965 (0.946–0.984) <0.001
Derived haemoglobin (g/dL) 14357 295 2.1 0.809 (0.758–0.862) <0.001
Anaemia
Yes 5505 183 3.3 1.824 (1.402–2.373) <0.001
No 8852 112 1.3 Reference
Fever
Yes 10569 173 1.6 0.594 (0.470–0.749) <0.001
No 7244 173 2.4 Reference
Sex
Female 8427 160 1.9 0.931 (0.754–1.149) 0.505
Male 9658 196 2.0 Reference
Hyperparasitaemia
Yes 1543 19 1.2 0.615 (0.384–0.984) 0.043
No 16845 342 2.0 Reference
Log10 parasitaemia (/μL) 18388 361 2.0 0.731 (0.619–0.864) <0.001
Weight-for-age score
Underweightb 8341 257 3.1 0.825 (0.744–0.915) <0.001
Yes 1418 80 5.6 1.768 (1.343–2.326) <0.001
No 6923 177 2.6 Reference
Region
Asia 3895 55 1.4 1.078 (0.356–3.263) 0.894
South America 615 8 1.3 0.482 (0.035–6.564) 0.584
Africa 13878 298 2.1 Reference
TIAa
Low 8406 64 0.8 0.371 (0.159–0.866) 0.022
Moderate 5120 129 2.5 0.746 (0.426–1.306) 0.305
High 4449 161 3.6 Reference
Multivariable model 14051 291 2.1
ACT:
AS-MQ 0.566 ( 0.225–1.420) 0.225
DP 2.029 (1.240–3.317) 0.005
AS-AQ: FDC 4.014 (2.398–6.719) <0.001
AL Reference
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Table 4 Factors associated with the development of gametocytaemia after enrolment in individuals without microscopically
detected gametocytes before treatment with artemisinin combination therapy (Continued)
Age
< 1 year 1.707 ( 0.778–3.747) 0.269
1–4 years 2.303 (1.208–4.392) 0.011
5–11 years 1.418 (0.795–2.527) 0.237
12+ years Reference
Derived haemoglobin (g/dL) 0.828 (0.774–0.886) <0.001
Fever 0.653 (0.503–0.848) 0.001
Log10 parasitaemia (/μL) 0.757 (0.624–0.917) 0.004
Cox regression mixed effects model for time to gametocytaemia
Nobs, Number of observations; Npos, Number of positive observations; Weight-for-age z-score, calculated using “igrowup” package developed by WHO [41]
in children < 5 years of age; Underweight, weight-for-age z-scores < –2; TIA, Transmission intensity areas. a Proportional hazards assumption not satisfied;
b In multivariable analysis: HR, 1.51; 95 % CI, 1.13–2.02; P = 0.005, after adjusting for covariates in the main model
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crease in gametocyte density) and the type of ACT given
(Additional file 5: Table S4, Fig. 3b). Compared to AL,
gametocytaemia clearance was significantly faster with
AS-MQ (AHR, 1.26; 95 % CI, 1.00–1.60; P = 0.054)
and slower with DP (AHR, 0.74; 95 % CI, 0.63–0.88;
P = 0.001) (Fig. 3b). For the AS-AQ FDC, the rate of
gametocytaemia clearance was significantly slower com-
pared to that of AS-MQ (HR, 0.64; 95 % CI, 0.48–0.85;
P = 0.002), and non-significantly slower compared to
AL (HR, 0.80; 95 % CI, 0.63–1.02; P = 0.072). The
overall observed proportion of patients who cleared
gametocytes by day 7 was 64.4 % for AL, 61.7 % for
AS-MQ, 52.3 % for DP, and 47.8 % for AS-AQ, while
by day 14 gametocytes were cleared by 85.7 %, 90.2 %,
70.3 %, and 72.1 % of patients, respectively.
Gametocytaemia in relation to asexual parasite clearance
time and treatment response
Asexual parasite clearance was rapid for all treatments
with 8.8 %, 9.1 %, 6.4 %, and 7.8 % of patients having re-
sidual asexual parasites after 2 days treatment with AL,
AS-MQ, AS-AQ-FDC, and DP, respectively. On day 3,
these figures were 0.8 %, 1.3 %, 0.4 %, and 0.7 %. Re-
sidual asexual parasite prevalence on day 1, 2 or 3 was
not associated with gametocytaemia clearance or the
appearance of gametocytaemia in univariable or multi-
variable analysis. Individuals who experienced PCR-
confirmed treatment failure by day 28 were more likely
to be gametocytaemic on any day during follow-up
(AOR, 2.12; 95 % CI, 1.08–4.34; P = 0.025) and develop
gametocytaemia after day 7 (AOR, 9.05; 95 % CI, 3.74–
21.91; P < 0.001) compared to patients with no recorded
recurrence and at least 28 days follow-up. Similarly, the
increased risk of gametocytaemia on any day during
follow-up (AOR, 1.95; 95 % CI, 1.37–2.77; P < 0.001) and
of developing gametocytaemia after day 7 (AOR, 3.03;
95 % CI, 1.66–5.54; P < 0.001) was observed in individualswith reinfection (Fig. 4a). This association was not ex-
plained by differences in artemisinin dosing. Gametocytae-
mia clearance in individuals with gametocytaemia prior to
treatment was not associated with treatment outcome
(Fig. 4b).
Assessment of potential bias
Attrition bias of the included studies is presented in
Additional file 6: Table S5. Although many studies were
not blinded, the blinding of the independent outcome la-
boratory assessments (i.e. microscopy readings to meas-
ure gametocytaemia and PCR classification of treatment
outcome are performed by laboratory staff not directly
involved in the study), minimize the risk of bias in out-
come assignment. We consider publication bias unlikely
since gametocytaemia measurements were a primary
outcome in only 2 (out of 121) publications and gameto-
cytaemia results are unlikely to have influenced the
decision to publish. Sensitivity analyses showed that ex-
clusion of any of the studies did not change the main
conclusions of the analysis (Additional file 7: Table S6).
Results for time to gametocytaemia were also con-
firmed for all covariates except for age when analysis
was restricted to individuals with complete weekly
data on gametocytaemia (Additional file 8: Table S7
and Additional file 9: Figure S2). The fact that the ef-
fect of age was lost may be due to a considerable loss
of observations in this sub-analysis that differed by
age groups: 12 %, 15 %, 33 %, and 32 % of patients
in groups <1 year, 1–4 years, 5–11 years, and ≥12 years of
age were not included in the sub-analysis.
Discussion
We analysed data from nearly 50,000 patients from trials
that included measures of gametocytaemia by blood
smears. The prevalence of gametocytaemia before and
after treatment was greatest in young patients, and those
with lower asexual parasite density, anaemia and absence
Fig. 4 Gametocyte carriage by treatment outcome. a Development of gametocytaemia after treatment; evaluated in patients with no gametocytes on
enrolment. b Clearance of gametocytaemia, adjusted for initial gametocyte count, evaluated in patients with gametocytaemia on enrolment
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and clearance of gametocytaemia was determined by the
type of ACT with AL and AS-MQ being most effica-
cious in preventing post-treatment gametocyte carriage.
Gametocytaemia is essential for onward transmission
of malaria infections to mosquitoes. Understanding fac-
tors that influence gametocytaemia prior to treatmentand the gametocytocidal properties of antimalarial drugs
is of great relevance for interventions that aim to reduce
malaria transmission. Mature P. falciparum gametocytes
first appear in the human bloodstream 7 to 15 days after
the initial wave of their asexual parasite progenitors.
This long maturation process and the impacts of hu-
man and parasite factors associated with gametocyte
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portion of malaria patients harbouring gametocytes upon
presentation with clinical illness. We observed that the
same host characteristics influenced gametocytaemia be-
fore and after treatment. The prevalence of gametocytae-
mia was higher in patients with anaemia and without
concurrent fever [4, 24]. Reduced haemoglobin concentra-
tions are often a consequence of prolonged duration of in-
fections or recurrent malaria episodes [25, 26], both
of which have been associated with increased gameto-
cyte production [4]. Anaemia may also be an inde-
pendent predictor of gametocytaemia [4, 27] since low
haemoglobin concentrations and reticulocytosis directly
stimulate gametocyte production [28, 29]. The association
between asexual parasite density at enrolment and
gametocytaemia was different in Asian and African
settings. In Asian studies, the prevalence of gametocytae-
mia showed a gradual negative association with asexual
parasite density [4], whilst in Africa, this negative associ-
ation was only apparent at asexual parasite densities above
5,000 parasites/μL. These setting-dependent patterns may
explain previous inconsistent reports on the association
between asexual parasite densities and gametocytae-
mia [4, 27, 30, 31]. These three predictors of gameto-
cytaemia (anaemia, lower asexual parasite density and
absence of fever) may all reflect chronic infections
that, because of their longer duration, may be more
likely to present with gametocytaemia. Host immunity
and the likelihood of super-infections vary signifi-
cantly with transmission intensity and both influence
asexual parasite densities and gametocyte dynamics.
Age is a useful surrogate of immunity. In African studies,
there was a gradual decrease in the prevalence of gameto-
cytaemia with increasing age, while in Asia, the prevalence
of gametocytaemia increased until approximately 20 years
of age followed by a general decline thereafter. Further
studies are needed to determine whether this pattern is
explained by host-factors or by age or occupation-
associated malaria exposure in Asian settings.
Patients presenting with gametocytaemia cleared their
gametocytaemia rapidly following ACT, with 57 % of
patients being gametocyte-free by day 7 and 88 % by
day 21. The rate of gametocytaemia clearance varied
significantly with the ACT regimen. Differential ef-
fects of ACT on post-treatment gametocytaemia have
been reported previously, but with contradicting results
[32–34]. Our large meta-analysis revealed that both the
appearance and duration of gametocytaemia were 2-fold
and 25 % lower, respectively, in AL- compared to DP-
treated patients. In individuals treated with DP, a lower
treatment dose was associated with an increased appear-
ance of gametocytaemia after treatment. We previously
demonstrated that treatment failure is also associated with
DP dosing [10] and the World Health Organizationrecently increased the dose recommendation for DP
to ensure a minimum of 7.5 mg/kg total dose of
dihydroartemisinin in children < 25 kg [35]. The ap-
pearance of gametocytaemia after AS-AQ FDC was
markedly more prevalent than after either AL or AS-MQ.
Furthermore, gametocytaemia clearance was slower after
AS-AQ FDC compared to AS-MQ. This striking differ-
ence of AS-AQ FDC compared to AL and AS-MQ could
not be explained by differences in total artemisinin dosing
or treatment outcome. These differential effects of ACTs
may relate to the frequency of artemisinin dosing or to the
activity of the non-artemisinin partner drug. In vitro drug
screening assays indicate similar activity of lumefantrine
and amodiaquine against mature gametocytes [36], whilst
developing gametocytes appear more susceptible to meflo-
quine and lumefantrine than to amodiaquine [37]. This
would suggest that the maturation of developing gameto-
cytes after initiation of treatment differs between ACT
regimens, and this has consequences for post-treatment
gametocytaemia.
Contrary to previous studies [38, 39], we found no
association between the rate of asexual parasite clear-
ance and gametocytaemia during follow-up. For chloro-
quine and sulphadoxine-pyrimethamine treatment, post-
treatment gametocytaemia and malaria transmission to
mosquitoes have been proposed as early parasitological
indicators of reduced drug sensitivity [40, 41]. In our
study, >98 % of all patients cleared their infections by
day 2 post-initiation of treatment. Patients subsequently
failing treatment were at 15-fold greater risk of gameto-
cytaemia than those successfully treated, and this was
similar for both PCR confirmed recrudescent and new
infections. The timing of gametocytaemia coincided with
the recurrent asexual parasitaemia. Since the earliest de-
velopmental stages of gametocytes are sequestered for
6–8 days in the bone marrow [42], this suggests that
gametocyte production started before reappearing asex-
ual parasites were detected by microscopy. The strong
association of gametocytaemia with recrudescent infec-
tions and new infections warns against a simplistic com-
parison of treatment regimens based on gametocytaemia
shortly after treatment. Initial treatment efficacy and
post-treatment prophylaxis that postpones new infec-
tion, and therefore de novo gametocyte production, are
important determinants of the impact of ACT regimens
on malaria transmission.
Whilst our analysis focuses on peripheral gametocytae-
mia, it is important to acknowledge that this is a surrogate
marker of malaria transmission potential. The infectivity
of persisting or appearing gametocytes may be affected by
the type of antimalarial treatment [9]. Antimalarial drugs
may also influence gametocyte sex-ratio [43], which is an
important determinant of transmission success, although
there is currently no evidence for a differential effect of
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available study that directly determined infectiousness to
mosquitoes after ACT regimens compared in this study
supports our findings, reporting a two-fold higher mos-
quito infection rate after DP compared to AL [18], which
is consistent with our finding of significantly higher risk of
gametocyte appearance after DP (AHR, 2.03; 95 % CI,
1.24–3.34; P = 0.005 compared to AL). Gametocyte dens-
ities commonly fluctuate around the microscopic thresh-
old for detection and the use of molecular gametocyte
detection tools would have uncovered a higher proportion
of gametocyte carriers [5] at densities capable of contrib-
uting to onward malaria transmission [44]. The addition
of a single low primaquine dose to ACT can substantially
reduce the duration of low density gametocytaemia after
treatment [45] and prevent transmission to mosquitoes
[46, 47] but primaquine is currently not routinely added
to ACTs for treatment of uncomplicated malaria. Import-
antly, although the gametocytocidal properties of first-line
ACTs may influence community-wide transmission
[16, 48], this effect may be modest if transmission is
largely driven by asymptomatic individuals who do not
seek treatment. The inclusion of these asymptomatically
infected individuals in treatment campaigns may have a
much larger impact on malaria transmission than the
choice of ACT for first-line treatment [6, 7].
Our analysis was purposefully restricted to microscopic
findings on gametocytaemia, for which most data are
available. Although this approach will have missed some
gametocyte carriers, this would not affect the comparison
of treatment arms. Studies where microscopy, molecular
gametocyte data and infectivity results are available indi-
cate that these methods lead to the same conclusions on
the comparative effects of antimalarials on post-treatment
gametocyte dynamics and infectivity [15, 18].
Conclusions
In conclusion, we identified independent risk factors for
the prevalence of gametocytaemia in patients with un-
complicated falciparum malaria in studies conducted on
three continents. AS-MQ and AL are superior ACT op-
tions in preventing gametocytes shortly after treatment
compared to DP or AS-AQ. We hypothesize that this
difference is due to the non-artemisinin partner drug
defining post-treatment gametocyte dynamics.
Additional files
Additional file 1: Table S1. Overview of all included studies. 1 The
sensitivity of microscopy methods was classified into one of four
categories: 1 = studies in which slides were specifically read for
gametocytes, reviewing at least 100 microscopic high power fields or
against ≥ 1000 white blood cells (WBC); 2 = microscopists specifically
instructed to record gametocytes but slides were primarily read forasexual parasites; ≥ 100 microscopic high power fields per ≥ 1000 WBC
were read; 3 =microscopists were specifically instructed to record
gametocytes; 50–99 microscopic high power fields per 500–999 WBC
were read; 4 =microscopists were not specifically instructed to record
gametocytes or the number of examined high power fields was < 50 or
the number of WBC was < 500. 2 All treatment combinations are loose,
unless stated. FDC, fixed dose combination. AS, Artesunate; MQ,
Mefloquine; AL, Artemether-lumefantrine; DP, Dihydrartemisinin-
piperaquine; SP, Sulphadoxine-pyrimethamine; AQcb, AQ co-blisterered
loose combination; HL, Halofantrine; QN, Quinine; AM, Artemether, AV,
Atovaquone; PG, Proguanil; CQ, Chloroquine; CDA, Chlorproguanil-
dapsone-artesunate; Tet, Tetracycline; CL, Clindamycine. Search strategy:
Published prospective trials were identified by the application of the key
terms ((malaria OR plasmod*) AND (amodiaquine OR atovaquone OR
artemisinin OR arteether OR artesunate OR artemether OR artemotil OR
azithromycin OR artekin OR chloroquine OR chlorproguanil OR cycloguanil
OR clindamycin OR coartem OR dapsone OR dihydroartemisinin OR
duo-cotecxin OR doxycycline OR halofantrine OR lumefantrine OR
lariam OR malarone OR mefloquine OR naphthoquine OR naphthoquinone
OR piperaquine OR primaquine OR proguanil OR pyrimethamine OR
pyronaridine OR quinidine OR quinine OR riamet OR sulphadoxine
OR tetracycline OR tafenoquine)) though the PubMed library. Studies
on prevention, prophylaxis, review, animal studies or patients with severe
malaria were excluded. (DOCX 155 kb)
Additional file 2: Figure S1. Relationship between gametocytaemia
on enrolment and baseline haemoglobin concentration, parasitaemia
and patient age. The predicted probability of gametocyte carriage at
enrolment is plotted from the multivariate model; the line indicates the
best fit, the shaded area the 95 % CI. Only patients from studies with
gametocyte detection sensitivity in category 1 or 2 were used for this
analysis (≥ 100 high power fields or ≥ 1000 WBC examined specifically for
gametocytes). For the analysis on age, only children < 5 years of age
were included in the analysis. (TIF 480 kb)
Additional file 3: Table S2. Independent risk factors for the prevalence
of gametocytaemia at enrolment in children aged 1–5 years. Logistic
multivariable analysis by region with prevalence of gametocytaemia at
enrolment as dependent variable. Nobs, Number of observations; Npos,
Number of positive observations. The relationship between gametocyte
prevalence at enrolment and age is statistically significant (P < 0.001)
although not linear, see Additional file 2: Figure S1. Malnutrition
(underweight) was not an independent predictor (AOR, 1.11; 95 % CI,
0.99–1.26; P = 0.083) in Africa and (AOR, 0.92; 95 % CI, 0.47–0.83; P = 0.823) in
Asia, after adjustment for age, haemoglobin, parasitaemia and fever (after
polynomial transformations, as presented in Additional file 2: Figure S1).
(DOC 28 kb)
Additional file 4: Table S3. The effect of treatment dosing on the
appearance of gametocytaemia in participants without microscopically
detected gametocytaemia before treatment (time to gametocytaemia)
and clearance of gametocytaemia in participants with gametocytaemia
at enrolment (time to clearance). All analyses of time to clearance are
adjusted for log of the initial gametocyte density. Nobs, Number of
observations; Npos, Number of positive observations. Under-dosed
defined as ≤ 8.4 mg/kg artemether dose in AL, < 6 mg/kg dose of
artesunate or DHA in other regimens [19]. In the multivariate model
estimates are adjusted for other covariates, for time to gametocytaemia:
covariates identified in the full final model presented in Table 4; for time to
clearance: ACT, since no other covariates other than ACT were identified in
the final model there were no multivariate models fitted within each ACT.
ND, No data, HR could not be estimated as there were no patients with
gametocytaemia in the under-dose/low-dose group. (DOC 86 kb)
Additional file 5: Table S4. Factors associated with the clearance of
gametocytaemia after enrolment in individuals who were gametocytaemic
before treatment with artemisinin combination therapy. Nobs, Number of
observations; N cleared, Number of patients with day of clearance of
gametocytaemia recorded. Derived haemoglobin, conversion from
haematocrit: haemoglobin = (haematocrit – 5.62)/2.60 [40]; Anaemia,
haemoglobin < 10 g/dL; Fever, temperature > 37.5 °C; Hyperparasitaemia,
parasitaemia > 100,000 parasites per μL; weight-for-age z-score, calculated
using “igrowup” package developed by WHO [41] in children < 5 years of
WWARN Gametocyte Study Group BMC Medicine  (2016) 14:79 Page 15 of 18age; Underweight, weight-for-age z-scores < –2. Proportional hazards
assumption not satisfied for transmission intensity areas, Region, and
artemisinin combination therapy. (DOC 59 kb)
Additional file 6: Table S5. Risk of bias in individual studies included in
the analysis. ACT, Artemisinin combination therapy. 1 For trials with non-
ACTs, data were only analysed for gametocytaemia on enrolment and
regimens, arms, randomization, concealment of treatment, sequence
generation and treatment blinding are given as not applicable (NA).
2 Includes exclusions due to study design (i.e. travellers, repeated episodes).
3 Evaluated in all patients except for exclusions due to study design or
protocol violations. 4 Evaluated on all included patients treated with ACT
and without gametocytaemia on enrolment. 5 Proportion of patients
with time to gametocyte data available but incomplete day 28
follow-up. 6 Evaluated on all included patients with gametocytaemia
on enrolment treated with ACT. 7 The sensitivity of microscopy methods
was classified into one of four categories: 1 = studies in which slides were
specifically read for gametocytes, reviewing at least 100 microscopic high
power fields or against≥ 1000 white blood cells (WBC); 2 =microscopists
specifically instructed to record gametocytes but slides were primarily read
for asexual parasites ; ≥ 100 microscopic high power fields per ≥1000 WBC
were read; 3 = microscopists were specifically instructed to record
gametocytes; 50–99 microscopic high power fields per 500–999 WBC
were read; 4 = microscopists were not specifically instructed to record
gametocytes or the number of examined high power fields was < 50 or
the number of WBC was < 500. 8No data, no patients with sufficient
gametocyte follow-up data that could be included in the analysis.
(PDF 408 kb)
Additional file 7: Table S6. Factors associated with the development
of gametocytaemia after enrolment in individuals who were gametocyte-
free before treatment with artemisinin combination therapy. Cox regression
model for time to gametocytaemia. Only patients with complete 28-day
follow-up are included. (DOC 35 kb)
Additional file 8: Table S7. Sensitivity analysis: variation in model
coefficients after exclusion of individual studies. 1 Estimates as obtained
in the final multivariate models and listed in main tables. 2 RSD, Relative
standard deviation was calculated as a ratio of standard deviation to
mean of the estimates (odds ratio or hazard ratio) calculated by fitting
models with one study excluded at a time. (DOC 44 kb)
Additional file 9: Figure S2. Development of gametocytaemia after
treatment evaluated in patients with no gametocytaemia on enrolment
and full 28-day follow-up. A: Development of gametocytaemia by
artemisinin combination therapy. B: Development of gametocytaemia
by treatment outcome. (TIF 284 kb)Acknowledgments
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